+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether combining pasritamig with docetaxel can extend the time before disease progression, measured by scans or death, compared to docetaxel alone in adults with metastatic castration-resistant prostate cancer. This type of prostate cancer continues to grow despite low male hormone levels. The study is a Phase 3 randomized trial designed to compare these treatments in this patient population. Participants are assigned to one of two groups. One group receives pasritamig together with docetaxel until disease progression or treatment end. The other group receives docetaxel plus prednisone or prednisolone as background medication. The study uses imaging scans and other criteria to monitor disease progression. The study treatment continues until certain protocol-defined endpoints are met. During the study, participants undergo various scans including CT, MRI, and bone scans to assess disease status. Researchers monitor progression-free survival and other outcomes such as overall survival, symptom progression, and quality of life using questionnaires. Safety is tracked by recording adverse events, lab abnormalities, and treatment side effects. Follow-up lasts up to about four and a half years, allowing comprehensive evaluation of treatment impact and safety.

Age: 18Years +All GendersPhase 3
165 locations
P

Actively Recruiting

This research evaluates whether adding axitinib to nivolumab maintenance treatment after initial therapy with nivolumab plus ipilimumab can improve response rates in patients with metastatic renal cell carcinoma mRCC who have not achieved a complete response or experienced disease progression. The study is a phase II, open-label trial that aims to increase partial response rates based on prior trial results. Participants are randomly assigned to one of two groups one group receives axitinib 5 mg twice daily orally in addition to nivolumab 480 mg intravenously every four weeks, while the other group continues with nivolumab alone at the same dose and schedule. Treatment continues until disease progression, unacceptable side effects, patient withdrawal, or physician decision. The trial plans to enroll 118 patients to detect meaningful differences between groups. Throughout the study, participants will be closely monitored with tumor assessments and health evaluations to measure outcomes such as progression-free survival, overall survival, depth and duration of response, and treatment-related adverse events. Follow-up includes tracking health status and life status from enrollment through treatment and up to 100 days after the last dose. The study is sponsored by Consorzio Oncotech and started in April 2023, with an estimated end date in April 2027.

Age: 18Years +All GendersPhase 2
23 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
D

Actively Recruiting

Healthy Volunteer

Researchers are developing and validating a language model called eCREAMLM designed to interpret emergency department electronic health records EHRs from adult patients treated between 2021 and 2023. This observational, retrospective study aims to see if the language model can accurately extract relevant information from free-text medical notes for research and clinical analysis across six languages. The study involves multiple centers across several European countries and addresses challenges in emergency medicine research due to high patient volume and limited staff for data collection. The eCREAMLM model will be created by training and fine-tuning existing open-source language models on billions of medical texts and millions of free-text notes from hospital records. Expert physicians will annotate thousands of clinical notes to guide the fine-tuning process. Once developed, the models accuracy will be validated by comparing its data extraction against physician annotations in 1,000 clinical notes. Data will be anonymized and pooled by language to protect patient privacy. Participants contribute by having their anonymized emergency department medical notes included in the study database. The researchers will analyze how well the language model fills out a virtual case report form compared to experts, using statistical measures of agreement. This process requires no active participation from patients. The study is expected to run until September 2027, with outcomes measured at one month after validation starts.

Age: 18Years +All Genders
8 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of TYRA-300 in adults with FGFR3 altered low grade, intermediate risk non-muscle invasive bladder cancer NMIBC. This phase 2, multicenter, open-label study focuses on patients who have specific genetic alterations in the FGFR3 gene and have a confirmed low-grade NMIBC tumor. The purpose is to better understand how this oral drug works in this specific group of bladder cancer patients. Participants will receive one of three self-administered daily doses of the study drug TYRA-300 as oral tablets 50 mg, 60 mg, or 70 mg. The study is randomized and parallel in design, with all participants receiving the active drug in different dose cohorts. The drug is taken daily and treatment effects will be assessed over time, with follow-up lasting up to 24 months in some cases. During the study, participants will undergo regular assessments to monitor the drugs effects and safety, including evaluations of tumor response and recurrence. Key measures include the rate of complete response at 3 months, overall response rates up to 24 months, and the duration of response. Safety will be monitored through adverse event tracking. Participants will be followed for up to two years to assess longer-term outcomes and any side effects associated with TYRA-300.

Age: 18Years +All GendersPhase 2
48 locations
E

Actively Recruiting

Researchers are studying mild traumatic brain injury TBI, a common reason for emergency department visits. The study focuses on how brain computed tomography CT scans are used to detect brain injuries in patients with mild TBI. It aims to analyze the variability of CT scan use across Italian emergency departments, evaluate existing scoring systems that guide CT use, and develop a new model to better predict patient outcomes after mild head trauma. The study observes adult patients with mild TBI who present to emergency departments. Researchers will collect data on CT scan use and assess the accuracy of current clinical decision tools like the Canadian CT Head Rule and NICE guidelines. They will then work to create an improved scoring system to help doctors decide when CT scans are necessary, aiming to reduce unnecessary radiation exposure and healthcare costs. Participants will be monitored from September 2025 through August 2027 with data collected on CT scan usage and patient outcomes. The study will validate existing scores between September 2026 and August 2027 and develop a new predictive score by August 2027. Researchers will review patient data, including Glasgow Coma Scale scores, to measure how well the new tool predicts clinically relevant events. The total study duration spans from January 2026 to August 2027.

Age: 18Years +All Genders
59 locations
I

Actively Recruiting

Researchers are observing patients with advanced or unresectable hepatocellular carcinoma HCC who have not received prior systemic treatment. The study evaluates how long it takes for clinical hepatic decompensation to occur, along with quality of life, effectiveness, and safety of the STRIDE regimen, which combines tremelimumab and durvalumab. This observational study is conducted across multiple centers in Italy and is sponsored by AstraZeneca. Patients receive the STRIDE treatment as part of routine clinical practice in Italy. This involves a single dose of tremelimumab 300 mg combined with durvalumab 1500 mg on the first day of the first cycle, followed by durvalumab alone every four weeks. The study observes this treatment over a period of up to 30 months, monitoring responses and safety outcomes. Participants are followed regularly for assessments including time to hepatic decompensation, overall survival, progression-free survival, tumor response, disease control, and safety measures. Data are collected from the start date until study completion, which may extend up to 33 months. Participants quality of life and treatment safety are also monitored throughout this period.

Age: 18Years - 100YearsAll Genders
24 locations
N

Actively Recruiting

Researchers are conducting a multicenter, observational study in Italy to collect detailed information on patients with bone metastases. The study aims to establish a national database to better understand clinical and biological factors related to primary tumors and their bone metastases. This research will also evaluate the impact of treatments and care pathways on skeletal events over a period of up to 15 years. Patients with bone metastases from solid tumors will be enrolled in this study and registered in a specialized online database. Each participant will be followed from enrollment until death or until they stop follow-up for other reasons. The study does not involve any experimental treatments but collects comprehensive data on patients conditions and care. Participants will provide informed consent and their medical data will be regularly recorded and analyzed. The study monitors clinical outcomes, skeletal-related events, and the efficiency of treatment pathways. Data collection will continue for up to 15 years, providing long-term insights into bone metastases and patient management.

Age: 18Years +All Genders
30 locations
P

Actively Recruiting

Researchers are evaluating whether valproic acid can improve the effectiveness of anti-EGFR treatments and help prevent or reverse resistance in patients with advanced or metastatic colorectal cancer who have RASBRAF wild-type tumors. This randomized phase 2 study includes patients eligible for a rechallenge treatment setting, aiming to better understand tumor responses and identify biomarkers through tissue and blood sample analysis. Participants will be randomly assigned to receive either standard treatment with irinotecan and panitumumab or the same treatment combined with valproic acid VPA. Irinotecan and panitumumab are given every two weeks, while VPA is taken orally daily with dose adjustments to reach target blood levels. The study includes a safety phase for the VPA combination, and treatment continues until disease progression, unacceptable side effects, or other reasons for stopping. Throughout the study, patients will undergo tumor assessments by CT or MRI scans every 8 weeks, blood tests, and quality of life questionnaires. Toxicities will be monitored during treatment and up to 4 weeks after. Blood and tissue samples will be collected to study biomarkers related to treatment response and side effects. Follow-up will continue until death, recording subsequent treatments, with the primary outcome measuring progression-free survival at 16 weeks.

Age: 18Years +All GendersPhase 2
8 locations